Ariad Pharmaceuticals, Inc.  

(Public, NASDAQ:ARIA)   Watch this stock  
Find more results for ARIA
-0.25 (-3.56%)
Real-time:   12:16PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.66 - 6.96
52 week 4.37 - 10.07
Open 6.90
Vol / Avg. 1.38M/3.32M
Mkt cap 1.25B
P/E     -
Div/yield     -
EPS -1.23
Shares 191.03M
Beta 1.73
Inst. own 70%
Jul 22, 2016
ARIAD Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
May 10, 2016
Q1 2016 ARIAD Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
May 10, 2016
Q1 2016 ARIAD Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Mar 17, 2016
ARIAD Pharmaceuticals Inc at Barclays Global Healthcare Conference - Webcast
Mar 9, 2016
ARIAD Pharmaceuticals Inc at Cowen Health Care Conference
Feb 24, 2016
ARIAD Pharmaceuticals Inc at RBC Capital Markets Healthcare Conference
Feb 23, 2016
Q4 2015 ARIAD Pharmaceuticals Inc Earnings Release
Feb 23, 2016
Q4 2015 ARIAD Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -164.01% -194.57%
Operating margin -144.07% -182.89%
EBITD margin - -172.15%
Return on average assets -42.77% -40.21%
Return on average equity - -
Employees 459 -
CDP Score - -


United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Officers and directors

Alexander J. Denner Ph.D. Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Paris Panayiotopoulos President, Chief Executive Officer, Director
Age: 41
Bio & Compensation  - Reuters
Manmeet S. Soni Chief Financial Officer, Executive Vice President, Treasurer
Age: 38
Bio & Compensation  - Reuters
Thomas J. DesRosier J.D. Executive Vice President, Chief Legal and Administrative Officer, Secretary
Age: 60
Bio & Compensation  - Reuters
Martin J. Duvall Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Maria E. Cantor Senior Vice President - Corporate Affairs
Age: 47
Bio & Compensation  - Reuters
Daniel M. Bollag Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 54
Bio & Compensation  - Reuters
Hugh M. Cole Senior Vice President, Chief Business Officer
Age: 50
Bio & Compensation  - Reuters
Frank G. Haluska M.D., Ph.D. Senior Vice President - Clinical Research and Development and Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Timothy P. Clackson Ph.D. President - Research and Development, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters